Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/cei.12803 http://scihub22266oqcxt.onion/10.1111/cei.12803 C4991522!4991522!27118513     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27118513&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Exp+Immunol 2016 ; 185 (3): 361-71 Nephropedia Template TP {{tp|p=27118513|t=2016. The complement receptor 3 (CD11b/CD18) agonist Leukadherin?1 suppresses human innate inflammatory signalling |pdf=|usr=}}{{27118513}} gab.com Text The complement receptor 3 (CD11b/CD18) agonist Leukadherin 1 suppresses human innate inflammatory signalling JO: Clin Exp Immunol http://www.kidney.de/pget.php?&tw=1&pmid=27118513 #FOAvip Complement receptor 3 (CR3, CD11b/CD18) is a multi?functional receptor expressed predominantly on myeloid and natural killer (NK) cells. The R77H variant of CD11b, encoded by the ITGAM rs1143679 polymorphism, is associated robustly with development of the autoimmune disease systemic lupus erythematosus (SLE) and impairs CR3 function, including its regulatory role on monocyte immune signalling. The role of CR3 in NK cell function is unknown. Leukadherin?1 is a specific small?molecule CR3 agonist that has shown therapeutic promise in animal models of vascular injury and inflammation. We show that Leukadherin?1 pretreatment reduces secretion of interferon (IFN)??, tumour necrosis factor (TNF) and macrophage inflammatory protein (MIP)?1? by monokine?stimulated NK cells. It was associated with a reduction in phosphorylated signal transducer and activator of transcription (pSTAT)?5 following interleukin (IL)?12?+?IL?15 stimulation (P < 0·02) and increased IL?10 secretion following IL?12?+?IL?18 stimulation (P < 0·001). Leukadherin?1 pretreatment also reduces secretion of IL?1?, IL?6 and TNF by Toll?like receptor (TLR)?2 and TLR?7/8?stimulated monocytes (P < 0·01 for all). The R77H variant did not affect NK cell response to Leukadherin?1 using ex?vivo cells from homozygous donors; nor did the variant influence CR3 expression by these cell types, in contrast to a recent report. These data extend our understanding of CR3 biology by demonstrating that activation potently modifies innate immune inflammatory signalling, including a previously undocumented role in NK cell function. We discuss the potential relevance of this to the pathogenesis of SLE. Leukadherin?1 appears to mediate its anti?inflammatory effect irrespective of the SLE?risk genotype of CR3, providing further evidence to support its evaluation of Leukadherin?1 as a potential therapeutic for autoimmune disease. Twit Text FOAVip The complement receptor 3 (CD11b/CD18) agonist Leukadherin 1 suppresses human innate inflammatory signalling ????Clin Exp Immunol http://www.kidney.de/pget.php?&tw=1&pmid=27118513 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27118513 #FOAvip English Wikipedia <ref>{{Cite pmid|27118513}}</ref> The complement receptor 3 (CD11b/CD18) agonist Leukadherin?1 suppresses human innate inflammatory signalling #MMPMID27118513 Roberts AL; Fürnrohr BG; Vyse TJ; Rhodes B Clin Exp Immunol 2016[Sep]; 185 (3): 361-71 PMID27118513show ga Complement receptor 3 (CR3, CD11b/CD18) is a multi?functional receptor expressed predominantly on myeloid and natural killer (NK) cells. The R77H variant of CD11b, encoded by the ITGAM rs1143679 polymorphism, is associated robustly with development of the autoimmune disease systemic lupus erythematosus (SLE) and impairs CR3 function, including its regulatory role on monocyte immune signalling. The role of CR3 in NK cell function is unknown. Leukadherin?1 is a specific small?molecule CR3 agonist that has shown therapeutic promise in animal models of vascular injury and inflammation. We show that Leukadherin?1 pretreatment reduces secretion of interferon (IFN)??, tumour necrosis factor (TNF) and macrophage inflammatory protein (MIP)?1? by monokine?stimulated NK cells. It was associated with a reduction in phosphorylated signal transducer and activator of transcription (pSTAT)?5 following interleukin (IL)?12?+?IL?15 stimulation (P < 0·02) and increased IL?10 secretion following IL?12?+?IL?18 stimulation (P < 0·001). Leukadherin?1 pretreatment also reduces secretion of IL?1?, IL?6 and TNF by Toll?like receptor (TLR)?2 and TLR?7/8?stimulated monocytes (P < 0·01 for all). The R77H variant did not affect NK cell response to Leukadherin?1 using ex?vivo cells from homozygous donors; nor did the variant influence CR3 expression by these cell types, in contrast to a recent report. These data extend our understanding of CR3 biology by demonstrating that activation potently modifies innate immune inflammatory signalling, including a previously undocumented role in NK cell function. We discuss the potential relevance of this to the pathogenesis of SLE. Leukadherin?1 appears to mediate its anti?inflammatory effect irrespective of the SLE?risk genotype of CR3, providing further evidence to support its evaluation of Leukadherin?1 as a potential therapeutic for autoimmune disease. äThe complement receptor 3 (CD11b/CD18) agonist Leukadherin?1 suppresse(epmc).pdf DeepDyve Pubget Overpricing